SOM
$116M—
SomnoMed
Sleep & respiratory
Mandibular advancement devices (MAD) for obstructive sleep apnea; sold in 28 countries
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$116M
Burn Rate
—
Shares Outstanding
219M
Pipeline Assets
2
3M Price
SOM.ASX$0.530-19.1% 3M
Low $0.530High $0.730
Pipeline Assets (2)
SomnoDent AvantObstructive sleep apnea (oral appliance)
ApprovedSomnoDent FlexObstructive sleep apnea (oral appliance)
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
SomnoDent Avant
Obstructive sleep apnea (oral appliance)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 competitor trialPhase 2+ · Non-ASX
Obstructive Sleep Apnea (Oral Appliance)1 active trial
1 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (2)
Rest Assure clinical study completion
UpcomingExpectedarrow_upwardHigh30 June 2026
Rest Assure efficacy monitoring FDA 510(k) submission
UpcomingExpectedarrow_upwardHigh31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|---|---|---|---|---|
| Rest Assure clinical study completion Connected oral appliance therapy study supporting efficacy monitoring claim for FDA 510(k) | data readout | Expected | arrow_upwardHigh |
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.